• Patient aged 18 years or over

• Patient who have been informed of the objectives and the conditions of the study and who did not object to its participation

• Patient diagnosed with one chronic inflammatory rheumatological (rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis) or chronic inflammatory bowel (Crohn's disease, ulcerative colitis) diseases

• Patient for whom the investigator has decided, with patient's agreement and prior to inclusion:

• Or to initiate adalimumab by prescribing a biosimilar (Adalimumab FK)

• Either to replace Humira® with a biosimilar (AdalimumabFK)